Tumor Metabolism-Rewriting Nanomedicines for Cancer Immunotherapy

[Image: see text] Cancer immunotherapy has become an established therapeutic paradigm in oncologic therapy, but its therapeutic efficacy remains unsatisfactory in the majority of cancer patients. Accumulating evidence demonstrates that the metabolically hostile tumor microenvironment (TME), characte...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Xiao, Xia, Shu, Du, Shubo, Zhu, Mao-Hua, Lai, Xing, Yao, Shao Q., Chen, Hong-Zhuan, Fang, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604035/
https://www.ncbi.nlm.nih.gov/pubmed/37901179
http://dx.doi.org/10.1021/acscentsci.3c00702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604035/
https://www.ncbi.nlm.nih.gov/pubmed/37901179
http://dx.doi.org/10.1021/acscentsci.3c00702

Ejemplares similares